The COVID-19 pandemic marked the start of a medical revolution – that of mRNA technology. As the significance of RNA and nucleic acid technology becomes clear, so too does the role of lipids and lipid nanoparticles (LNPs), which ensure the safe delivery of the unstable RNA-based active ingredients into cells.
Researchers from the University of Mainz in Germany are studying ways to modify the polyethylene glycol (PEG) lipids that form part of LNPs to improve drug efficacy and immune response. In this webinar, technical experts will introduce these new PGME polymers, poly(glycidyl methyl ether), as a highly promising alternative to standard PEGs for use in RNA delivery. Furthermore, they will highlight current advances in leveraging these so-called rPEGs (randomized PEGs) in LNP-based delivery systems.